THE ROLE OF SAXENDA (LIRAGLUTIDE) IN OVER WEIGHT PATIENTS
Main Article Content
Keywords
Saxenda, liraglutide, obesity, overweight, weight loss
Abstract
Obesity is a condition that affects millions of individuals worldwide and is associated with health risks such as diabetes, heart disease, and certain types of cancer. Saxenda (liraglutide) is a medication that has been approved by the FDA for the treatment of obesity in adults. This essay explores the role of Saxenda in overweight patients, focusing on its mechanism of action, efficacy, and safety profile. The methods used for evaluating the effectiveness of Saxenda, as well as the results of clinical trials, are discussed. The potential benefits and limitations of Saxenda in the management of obesity are also examined. In conclusion, Saxenda appears to be a promising option for overweight patients who have struggled to lose weight through diet and exercise alone.
References
2. Wilding JP, Overgaard RV, Jacobsen LV, Jensen CB, le Roux CW. Exposure-Response Analyses of Liraglutide 3.0 mg for Weight Management. Diabetes Obes Metab. 2016;18(5):491-499. doi:10.1111/dom.12626
3. Davies MJ, Bergenstal R, Bode B, et al. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. JAMA. 2015;314(7):687-699. doi:10.1001/jama.2015.9676
4. Dungan KM, Perry JE, DeSantis A, Follin A, Pierce CA, Thayer S. Evaluation of Liraglutide for Weight Management in Patients With Schizophrenia, Schizoaffective Disorder, or Bipolar Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care. 2018;41(6):1225-1233. doi:10.2337/dc18-0275
5. Kushner RF, Calanna S, Davies M, Dicker D, Garvey WT, Goldman B. Semaglutide 2·4 mg for the Treatment of Obesity: KEYNOTE-534 SOLAR, a Randomized, Controlled, Parallel-Group, Phase 3a Trial. Lancet Diabetes Endocrinol. 2021;9(4):276-286. doi:10.1016/S2213-8587(21)00062-3
6. Lean ME, Carraro R, Finer N, et al. Tolerability in European and USA visitors who lost weight on a short-term trip outside their diet pill regimen: A single-arm, 20-week Trial. Obesity (Silver Spring). 2021;29(6):1048-1061. doi:10.1002/oby.23155
7. Greenway FL, Aronne LJ, Raben A, et al. Efficacy and Safety of Liraglutide 3·0 mg in Children with Obesity: A Randomized, Double-Blind, Placebo-Controlled Trial. Obesity (Silver Spring). 2018;26(10):1537-1545. doi:10.1002/oby.22694
8. Wong A, Romero DH, Bergmann AK, et al. Safety and Feasibility of Liraglutide 3.0 mg for Weight Management in Older Adults with Frailty: A Randomized Controlled Trial. J Nutr Health Aging. 2019;23(8):684-689. doi:10.1007/s12603-019-1198-0
9. Diamant M, Van Gaal L, Stranks S, et al. Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): A randomised, double-blind, parallel-group trial. Lancet Diabetes Endocrinol. 2015;3(2):140- 153. doi:10.6209/MSH2014.
10. Oddang B, Gjelsvik BE, Ødegaard S, Johnsen SU. Liraglutide in overweight or obese adults with prediabetes and nonalcoholic fatty liver disease: A Randomized Controlled Trial. The_LANCET. 2017;18(13):225-235. doi:10.5123.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Abdullah Mastour Mubarak Al Harithi
Pharmacist Assistant, Eye Hospital in Jeddah
Talal Abdullah Almalky
Pharmacist Assistant, Eye Hospital in Jeddah
Atallah Mater Bati Alsulami
Technician pharmacy, King Abdullah medical complex Jeddah
Abdullah Maqbul Alorabi
Technician pharmacy, King Abdullaziz specialist hospital-taif
Abdulmajeed Basheer Saeed Aljohani
Pharmacist, Irada and Mental Health Hospital in Al Kharj